297 related articles for article (PubMed ID: 17498667)
21. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
22. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
23. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
24. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
27. Cancer treatment of the future: inhibitors of histone methyltransferases.
Spannhoff A; Sippl W; Jung M
Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
[TBL] [Abstract][Full Text] [Related]
28. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
31. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
34. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?
Grayson DR; Kundakovic M; Sharma RP
Mol Pharmacol; 2010 Feb; 77(2):126-35. PubMed ID: 19917878
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
36. Targeting the epigenome for the treatment and prevention of lung cancer.
Schrump DS; Nguyen DM
Semin Oncol; 2005 Oct; 32(5):488-502. PubMed ID: 16210090
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Marks PA
Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
[TBL] [Abstract][Full Text] [Related]
38. Sensitization of tumor cells by targeting histone deacetylases.
Perego P; Zuco V; Gatti L; Zunino F
Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
[TBL] [Abstract][Full Text] [Related]
39. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
Huang L
J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
[TBL] [Abstract][Full Text] [Related]
40. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
